Background
==========

Squamous cell carcinoma (SCC) is the most common neoplasm of the conjunctiva \[[@B1]\]. The etiology of cancer of the conjunctiva appears to be multifactorial; several risk factors have been identified, such as smoke, Human immunodeficiency virus (HIV) infection, Ultraviolet (UV) light, history of pterygium, or Human papillomavirus infection (HPV) \[[@B2],[@B3]\]. However, the reports on HPV and conjunctival neoplasms are controversial. Some studies have reported a heterogeneous prevalence of high-risk HPV types, suggesting that only a subset of cases can be attributed to these viruses \[[@B4],[@B5]\]. Differences in detection methods, populations, or geographic distribution could contribute to the variation in HPV infection rates in Conjunctival Squamous Cell Carcinoma (SCC)\[[@B6]-[@B12]\]. HPV is considered the main etiologic agent in proliferative ocular surface, lachrymal sac lesions, and pterygium worldwide, and it is has been suggested that HPV types 16 and 18 play a critical role in the oncogenesis of conjunctival cancers \[[@B13]-[@B17]\].

HPV are a group of host-specific DNA viruses with oncogenic subtypes that have been shown to act as carcinogens in the development of Cervical Cancer (CC), anogenital, head and neck, and CSCC \[[@B18],[@B19]\]. While the E6 oncoprotein, encoded by HPV16 or HPV18, is known to bind the cancer gene product *p53*and to promote its degradation, the E7 oncoprotein binds to the retinoblastoma cancer gene product *pRB*and results in E7-induced *pRB*inactivation. The E5 virus protein cooperates with E7 to transform cells and enhances the ability of E7 to induce proliferation, and with E6, to immortalize cells \[[@B20]\]. Preclinical and clinical studies suggest that the adoption of HPV vaccination strategies may exert an impact on the incidence of CC and potentially on other HPV infection-associated cancers, such as conjunctival cancer \[[@B21]\].

In order to elucidate the presence of HPV in CSCC, in the present study a group of fixed and paraffin-embedded specimens from Mexican patients with CSCC were analyzed, and a systematic review of the literature was performed.

Results
=======

Prevalence of HPV Infection in Conjunctival Carcinoma Worldwide
---------------------------------------------------------------

The PubMed database (National Library of Medicine, Bethesda, MD, USA) was used to identify all of the articles published between 1986 and August 2011 containing combinations of the Medical Subject Headings \"Human papillomavirus\" and \"Conjunctival carcinoma\". All articles reporting data of HPV prevalence in conjunctival carcinomas were selected and reviewed (45 reports). To have a more robust analysis, publications containing \< 10 studied cases were excluded from the analysis. Finally, 21 articles were included in this review. Information on country of origin, year, authors, sample size, and mucosal and cutaneous HPV prevalence was retrieved (Table [1](#T1){ref-type="table"}).

###### 

Geographic distribution of Human Papillomavirus in conjunctiva carcinoma

  Continent   Authors           Year   N cases   HPV cutaneous prevalence   HPV mucosal prevalence   Countries
  ----------- ----------------- ------ --------- -------------------------- ------------------------ ----------------
  African     Yu JJ             2010   11        0                          9 (81%)                  Uganda, Kenya
              Ateenyi-Agaba C   2010   94        42 (44.7%)                 6 (6.4%)                 Uganda
              DeKoning MN       2008   24        10 (42%)                   3 (13%)                  Uganda
              Tornesello ML     2006   29        3 (10.3%)                  0                        Uganda
              Moubayeb P        2004   14        0                          5 (35%)                  Tanzania
              Ateenyi-Agaba C   2004   21        0                          18 (86%)                 Uganda
              Newton R          2002   39        0                          11 (28%)                 Uganda
              Waddell KM        1996   20        0                          7 (35%)                  Uganda, Malawi
  Europe      Reszec J          2010   38        0                          2 (5.2%)                 Poland
              Guthoff R         2009   31        0                          0                        Germany
              Reszec J          2005   11        0                          1 (9%)                   Poland
              Toth J            2000   23        0                          5 (22%)                  Hungary
  Asia        Manderwad GP      2009   48        0                          0                        India
              Sen S             2007   30        0                          0                        India
              Jung SM           2006   13        0                          0                        Taiwan
              Tulvatana W       2002   30        0                          0                        Thailand
              Eng HL            2002   20        0                          0                        China
              Karcioglu ZA      1997   31        0                          17 (55%)                 Saudi Arabia
  Oceania     Tabrizi SN        1997   88        0                          34 (39%)                 Australia
  America     Palazzi MA        2000   31        0                          4 (12%)                  Brazil
              McDonell JM       1992   11        0                          7 (63%)                  USA
              Present work      2011   36        0                          8 (22%)                  Mexico

Publications containing less than ten cases studied were excluded from the analysis. In total were 21 reports covering more than 650 cases with an average of 28% in 15 countries. A range from 0-86% was observed

Detection of HPV Sequences in Conjunctival Carcinomas of Mexican Patients
-------------------------------------------------------------------------

To demonstrate the quality of the DNA for amplification reaction, DNA purified from formalin-fixed tissue samples was first subjected to PCR utilizing D-loop mitochondrial primers. This amplicon was consistent in all cases (Figure [1](#F1){ref-type="fig"}). Therefore, DNA was analyzed for the presence of HPV16/E6 (primers yielding a 126 bp fragment). These primer sets allowed detection of HPV DNA in 22% of the CSCC samples (8/36). Even when excessive DNA fragmentation was due to the tissue fixation process, our results might be considered as valid in showing the prevalence of HPV in the CSCC analyzed. In general, HPV16 was the sole type detected in CSCC samples (8/36, 22%). HPV type was confirmed by DNA sequencing (data not shown).

![**Illustrative example of PCR reaction for the HPV16/E6 region and D-loop mitochondrial region in conjunctival carcinoma samples**. Lanes 1, 2, 3 and 6 correspond to positive HPV16 samples (126 bp); lanes 4 and 5 correspond to negative HPV16 samples; all the samples were positive to mitochondrial region amplification (150 bp). Positive HPV16 (Caski) and negative HPV (C33) controls were included. MW: molecular weight marker 100 bp.](1750-9378-6-24-1){#F1}

Correlation Between HPV Detection and Clinicopathological Variables
-------------------------------------------------------------------

The age of patients ranged from 24-92 years, with a mean age of 66 years. Distribution by age group was as follows: 25% (*n*= 9), \> 80 years of age; 61% (*n*= 22), aged between 50 and 79 years, and only 14% (*n*= 5) were \< 49 years of age. Patients positive or negative to HPV infection were stratified by age group (Table [2](#T2){ref-type="table"}).

###### 

Correlation between HPV detection and clinicopathological variables in conjunctival cancer samples.

  ---------------------------------------------------------------
  Clinicopathological\                    HPV        
  variables                                          
  ---------------------------------- ---- ----- ---- ------------
  All cases                          36   8     28   

  **Age**                                            0.36

  ≤ 50                               9    3     6    

  \> 50                              27   5     22   

  **Gender**                                         0.84

  Male                               26   6     20   

  Female                             10   2     8    

  **Subtype Clinical**                               **0.03\***

  Limbus                             21   2     19   

  Conjunctive                        15   6     9    

  **Histological differentiation**                   0.49

  Well                               10   3     7    

  Moderate/Poor                      26   5     21   
  ---------------------------------------------------------------

HPV: human papillomavirus presence. \* Statistical significance

Anatomical analysis showed that in CSCC, limbus type was 58% (21/36), followed by conjunctival type, 42% (Table [2](#T2){ref-type="table"}). None of the patients had a previous history of pterygium. Sexual transmitted diseases (STD) history was not considered because the STD data provided was not considered accurate. Significant association was found between HPV detection and limbus subtype (*p*\< 0.05), but no statistically significant correlation between HPV and differentiation degree was found (*p*\> 0.05) (Table [2](#T2){ref-type="table"}).

Discussion
==========

Development of CSCC such as cervical cancer could be strongly linked with infection by high-risk HPV types \[[@B22]\]. There is molecular evidence that viral oncoproteins E6 and E7, found in high-risk HPV genotypes that are inactive cancer genes *p53*and *pRb*, promote genomic rearrangement and confer replicative and immortalizing activities on cervical neoplasms and other cancers \[[@B20]\]. According to the model of cervical carcinogenesis, which assigns HPV infection a central initiating role, identical or similar mechanisms could be responsible for the development of conjunctival cancer.

In reviewing the literature on CSCC and its relationship with HPV, it is evident that a major discrepancy exists among the reports published. Intriguingly, in published data on HPV DNA analysis in conjunctival carcinoma, \< \< 1,000 samples were studied in nearly 21 reports, showing serious differences. Based on the present study and certain other reports that failed to demonstrate the HPV DNA of any HPV (mucosal or not), as in studies in Taiwan, Thailand, China, India, or Germany, we tend to conclude that HPV is highly, but not conclusively, unlikely to play any causal role in the pathogenesis of conjunctival cancer \[[@B6],[@B8],[@B13],[@B15],[@B23]-[@B25]\]. Even when HIV infection could act as an important risk factor for conjunctival cancer, reports showing a high percentage of HPV DNA sequences in CSCC HIV+ could indicate a biased result with respect to HPV frequencies \[[@B4],[@B26]\].

It is noteworthy that Mexico is a country with a high incidence of CC \[[@B27]\]; however, in the present work we show a low percentage of mucosal HPV sequences, mainly HPV 16 (22%) in conjunctival carcinoma. Interestingly, limbus tumor was found related with the presence of HPV; this association could be explained because limbus tissue is quite similar in concept to that of transitional epithelium, as in cervical epithelium. The low frequency of HPV DNA in conjunctival cancer in our Mexican population failed to support HPV as a relevant etiological factor for this tumor type. Additional studies will be required prior to there being a definitive relationship between HPV and conjunctival cancer.

Methods
=======

Tissues and DNA extraction
--------------------------

We analyzed 36 CSCC formalin-fixed paraffin-embedded specimens for HPV DNA detection. The samples were collected (during 2004-2008) from the Department of Pathology archives of the Hospital de la Luz, S.S., at Mexico City. All patients were subjected to surgery. All the samples consisted of the invasive conjunctiva squamous cell carcinoma. At present, the patients abandoned the clinical assistance, because they were free-disease. A tissue section of each specimen was hematoxilin and eosin stained and blindly analyzed by two independent pathologists to confirm the diagnosis. Information of clinical variables such as age, gender, sexually transmitted diseases, subtype clinical, histological differentiation and pterygium history were collected; in some cases the information were not available. Two 10 μm non-stained tissue sections were mounted on clean slides deparaffinized and rehydrated by standard methods. To avoid false negatives, defined tumor areas were manually microdissected under the light microscope (20× objective) with an sterilized needle, the scrapped tissue was then collected in a microtube containing 500 μl of digestion buffer (100 mM NaCl, 10 mM Tris-Cl pH 8, 25 mM EDTA pH 8, 0.5% SDS, and 0.1 mg/ml proteinase K), and incubated at 55°C for 48 hours. The DNA was extracted by means of Wizard Extraction kit (Promega, Madison WI, USA) according to manufacturers.

HPV detection and typing
------------------------

The presence of HPV DNA was determined by PCR analysis with consensus primers HPV16/E6 \[[@B28]\], which amplify, a fragment of E6 gene of 126 bp of HPV16. The PCR solution contained: 200 ng of tumor DNA, 1× buffer (50 mM KCl, 10 mM Tris- HCl, 0.1% Triton X-100), 2 mM MgCl~2~, 0.2 mM of each dNTP, 50 pmol of each primer and 2 units of Taq DNA polymerase (Promega) in 50 μl of final volume. The reaction tubes were placed in a thermal cycler (MJ Research Minicycler) with the following program: one cycle of denaturing at 94°C for 30 sec, and 40 cycles of denaturation at 94°C for 4 min, annealing at 55°C for 1.5 min, and extension at 72°C for 1.5 min, with a final extension at 72°C for 1.5 min. CaSKi DNA (HPV16+) was used as a positive control, C33 (HPV-), and lymphocyte DNA were included as negative controls. Before HPV detection, primers for human D-loop mitochondrial region genes were used as internal controls to monitoring DNA quality.

Statistical analysis
--------------------

All comparisons for significance were performed by means Χ^2^-test. All p values represent two-tailed test and were considered significant at 0.05. The statistical analysis was performed using the SPSS v15 statistical software.
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